Hurvitz Chaim's Form 4 filing
NRX Pharmaceuticals, Inc. (NRXP) · filed Sep 11, 2023
- Accession no.
- 0001415889-23-013137
- Filed
- Sep 11, 2023, 9:15 AM ET
- Trade date
- Aug 30, 2023
- Filing delay
- 12 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $20.1K. It was filed 12 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hurvitz ChaimCIK 0001630542 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 30, 2023 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +70,000 | $0.2875 | +$20,125 | 570,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.